In Phase I, which objective may be conducted as a secondary objective?

In Phase I, which objective may be conducted as a secondary objective?

• A. Estimation of initial safety and tolerability
• B. Assessment of Pharmacodynamics
• C. Early Measurement of Drug Activity
• D. Pharmacokinetics

Answer: (B)

In Phase I trials, the main focus is safety and how the drug behaves in the body, while any assessment of what the drug does to the body biologically is typically added as a secondary objective. Pharmacodynamics measures the drug’s biological effects and helps establish early dose–response relationships without turning the study into an efficacy trial. This makes pharmacodynamics a natural secondary objective alongside the primary safety/tolerability aims and the primary pharmacokinetics data that often guide dosing decisions. Estimation of initial safety and tolerability is usually a primary objective because confirming that the drug is acceptably safe at increasing doses is the core purpose of Phase I. Pharmacokinetics is also generally a primary objective since understanding absorption, distribution, metabolism, and excretion is essential for dosing and safety considerations. The concept of an “early measurement of drug activity” aligns with pharmacodynamics, but the standard framework in Phase I planning treats pharmacodynamics as the secondary objective that provides insight into the drug’s effects and supports interpretation of PK data.

In Phase I trials, the main focus is safety and how the drug behaves in the body, while any assessment of what the drug does to the body biologically is typically added as a secondary objective. Pharmacodynamics measures the drug’s biological effects and helps establish early dose–response relationships without turning the study into an efficacy trial. This makes pharmacodynamics a natural secondary objective alongside the primary safety/tolerability aims and the primary pharmacokinetics data that often guide dosing decisions.

Estimation of initial safety and tolerability is usually a primary objective because confirming that the drug is acceptably safe at increasing doses is the core purpose of Phase I. Pharmacokinetics is also generally a primary objective since understanding absorption, distribution, metabolism, and excretion is essential for dosing and safety considerations. The concept of an “early measurement of drug activity” aligns with pharmacodynamics, but the standard framework in Phase I planning treats pharmacodynamics as the secondary objective that provides insight into the drug’s effects and supports interpretation of PK data.